Anti-angiogenic agents in ovarian cancer: dawn of a new era?
J Liu, UA Matulonis - Current oncology reports, 2011 - Springer
Epithelial ovarian cancer is a leading cause of cancer-related death for women both in the
United States and worldwide, and the effectiveness of cytotoxic chemotherapy has …
United States and worldwide, and the effectiveness of cytotoxic chemotherapy has …
Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer
ARM van der Bilt, EGE de Vries, S de Jong… - Critical reviews in …, 2012 - Elsevier
Despite efforts to improve chemotherapeutic efficacy in epithelial ovarian cancer, outcome
for patients with advanced disease has remained unchanged since the introduction of …
for patients with advanced disease has remained unchanged since the introduction of …
Ovarian cancer: advances in first-line treatment strategies with a particular focus on anti-angiogenic agents
FJ Collinson, J Seligmann, TJ Perren - Current oncology reports, 2012 - Springer
Ovarian cancer is an important health concern worldwide. The majority of patients present
with advanced disease, and despite initial chemosensitivity, most relapse and die from their …
with advanced disease, and despite initial chemosensitivity, most relapse and die from their …
Angiogenesis inhibitors in the treatment of epithelial ovarian cancer
ES Han, M Wakabayashi, L Leong - Current treatment options in oncology, 2013 - Springer
Opinion statement Treatment of epithelial ovarian cancer involves surgical management
with staging or debulking surgery and chemotherapy with a platinum and taxane-containing …
with staging or debulking surgery and chemotherapy with a platinum and taxane-containing …
Antiangiogenic drugs in ovarian cancer
M Markman - Expert Opinion on Pharmacotherapy, 2009 - Taylor & Francis
Background: There is a critical need to develop effective new strategies for the management
of patients with advanced epithelial ovarian cancer. Objective: The purpose of this …
of patients with advanced epithelial ovarian cancer. Objective: The purpose of this …
Development of antiangiogenic agents for ovarian cancer
FJ Collinson, GD Hall, TJ Perren… - Expert review of …, 2008 - Taylor & Francis
Epithelial ovarian cancer (EOC) remains a major source of cancer morbidity and mortality,
despite advances in surgical and chemotherapeutic management. The molecular pathways …
despite advances in surgical and chemotherapeutic management. The molecular pathways …
Emerging therapies: angiogenesis inhibitors for ovarian cancer
AL Jackson, EL Eisenhauer… - Expert opinion on …, 2015 - Taylor & Francis
Introduction: Patients with epithelial ovarian cancer (EOC) have a high rate of recurrence,
and overall survival remains at∼ 25%. There is a need for new treatments that can increase …
and overall survival remains at∼ 25%. There is a need for new treatments that can increase …
Antiangiogenic strategies in epithelial ovarian cancer: mechanism, resistance, and combination therapy
C Jin, M Yuan, H Bu, C Jin - Journal of Oncology, 2022 - Wiley Online Library
Angiogenesis is one of the hallmarks of cancer and plays a crucial role in carcinogenesis
and progression of epithelial ovarian cancer. Antiangiogenic agent is the first approved …
and progression of epithelial ovarian cancer. Antiangiogenic agent is the first approved …
[HTML][HTML] Anti-angiogenic agents in ovarian cancer: past, present, and future
BJ Monk, LE Minion, RL Coleman - Annals of oncology, 2016 - Elsevier
Angiogenesis plays a pivotal role in normal ovarian physiology as well as in the progression
of ovarian cancer through ascites formation and metastatic spread. Bevacizumab (Avastin® …
of ovarian cancer through ascites formation and metastatic spread. Bevacizumab (Avastin® …
Antiangiogenic therapy for ovarian cancer
DD Rosa, AR Clamp, F Collinson… - Current opinion in …, 2007 - journals.lww.com
Data from preclinical and clinical studies reported in the last 2 years demonstrate the
importance of several proangiogenic factors in the prognosis of ovarian cancer, suggesting …
importance of several proangiogenic factors in the prognosis of ovarian cancer, suggesting …